Form and flexibility in phosphoinositide 3-kinases

Biochemical Society Transactions

Volumn 37, Issue 4, 2009, Pages 615-626

  Williams, Roger ^a   Berndt, Alex ^a   Miller, Simon ^a   Hon, Wai Ching ^a   Zhang, Xuxiao ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Cancer; P110; P85; Phosphoinositide 3,4,5 trisphosphate; Phosphoinositide 3 kinase (PI3K)

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHOSPHOINOSITIDE;

ARTICLE; CATALYSIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SELECTION; CELL SHAPE; CELL SURVIVAL; ENZYME ACTIVE SITE; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; PHOSPHATIDYLINOSITOL PHOSPHATES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SIGNAL TRANSDUCTION;

EID: 70349335444     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0370615     Document Type: Article

References (110)

1. Walker, E.H., Perisic, O., Ried, C., Stephens, L. and Williams, R.L. (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313-320
2. Marone, R., Cmiljanovic, V., Giese, B. and Wymann, M.P. (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784, 159-185
3. Hawkins, P.T., Anderson, K.E., Davidson, K. and Stephens, L.R. (2006) Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647-662
4. Cantley, L.C. (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657
5. Knight, Z.A., Gonzalez, B., Feldman, M.E., Zunder, E.R., Goldenberg, D.D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B. et al. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733-747
6. Jackson, S.P., Schoenwaelder, S.M., Goncalves, I., Nesbitt, W.S., Yap, C.L., Wright, C.E., Kenche, V., Anderson, K.E., Dopheide, S.M., Yuan, Y. et al. (2005) PI 3-kinase p110β: a new target for antithrombotic therapy. Nat. Med. 11, 507-514
7. Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H. et al. (2008) Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci. Signaling 1, ra3
8. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, M.D. et al. (2002) Impaired B and T cell antigen receptor signaling in p110α PI 3-kinase mutant mice. Science 297, 1031-1034
9. Ji, H., Rintelen, F., Waltzinger, C., Bertschy Meier, D., Bilancio, A., Pearce, W., Hirsch, E., Wymann, M.P., Ruckle, T., Camps, M. et al. (2007) Inactivation of PI3Kα and PI3Kδ distorts T-cell development and causes multiple organ inflammation. Blood 110, 2940-2947
10. Kim, M.S., Radinger, M. and Gilfillan, A.M. (2008) The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol. 29, 493-501
11. Li, Z., Jiang, H., Xie, W., Zhang, Z., Smrcka, A.V. and Wu, D. (2000) Roles of PLC-2 and -3 and PI3K in chemoattractant-mediated signal transduction. Science 287, 1046-1049
12. Hirsch, E., Katanaev, L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., Sozzani, S., Mantovani, A., Altruda, F. and Wymann, M.P. (2000) Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287, 1049-1053
13. Sasaki, T., Irie-Sasaki, J., Jones, R.G., Oliveira-dos-Santos, A.J., Stanford, W.L., Bolon, B., Wakeham, A., Itie, A., Bouchard, D., Kozieradzki, I. et al. (2000) Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046
14. Thomas, M.S., Mitchell, J.S., DeNucci, C.C., Martin, A.L. and Shimizu, Y. (2008) The p110γ isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J. Leukocyte Biol. 84, 814-823
15. Papakonstanti, E.A., Zwaenepoel, O., Bilancio, A., Burns, E., Nock, G.E., Houseman, B., Shokat, K., Ridley, A.J. and Vanhaesebroeck, B. (2008) Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J. Cell Sci. 121, 4124-4133
16. Ferguson, G.J., Milne, L., Kulkarni, S., Sasaki, T., Walker, S., Andrews, S., Crabbe, T., Finan, P., Jones, G., Jackson, S. et al. (2007) PI(3)Kγ has an important context-dependent role in neutrophil chemokinesis. Nat. Cell Biol. 9, 86-91
17. Yu, J., Wjasow, C. and Backer, J.M. (1998) Regulation of the p85/ p110α phosphatidylinositol 3′-kinase: distinct roles for the N-terminal and C-terminal SH2 domains. J. Biol. Chem. 273, 30199-30203
18. Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., Meek, S., Smith, A.J., Okkenhaug, K. and Vanhaesebroeck, B. (2008) The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl. Acad. Sci. U.S.A. 105, 8292-8297
19. Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S., Fukui, Y., Ui, M., Hazeki, O. and Katada, T. (1997) Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110β is synergistically activated by the βγ subunits of G proteins and phosphotyrosyl peptide. J. Biol. Chem. 272, 24252-24256
20. Maier, U., Babich, A. and Nurnberg, B. (1999) Roles of non-catalytic subunits in Gβγ,-induced activation of class I phosphoinositide 3-kinase isoforms β and γ. J. Biol. Chem. 274, 29311-29317
21. Miled, N., Yan, Y., Hon, W.C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H.J., Backer, J.M. and Williams, R.L. (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242
22. Geering, B., Cutillas, P.R., Nock, G., Gharbi, S.I. and Vanhaesebroeck, B. (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. U.S.A. 104, 7809-7814
23. Stephens, L.R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell, J., Smrcka, A.S., Thelen, M., Cadwallader, K., Tempst, P. and Hawkins, P.T. (1997) The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89, 105-114
24. Suire, S., Coadwell, J., Ferguson, G.J., Davidson, K., Hawkins, P. and Stephens, L. (2005) p84, a new Gβγ-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110γ. Curr. Biol. 15, 566-570
25. Voigt, P., Dorner, M.B. and Schaefer, M. (2006) Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase γ that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281, 9977-9986
26. Voigt, P., Brock, C., Nurnberg, B. and Schaefer, M. (2005) Assigning functional domains within the p101 regulatory subunit of phosphoinositide 3-kinase γ. J. Biol. Chem. 280, 5121-5127
27. Johnson, C., Marriott, S.J. and Levy, L.S. (2007) Overexpression of p101 activates PI3Kγ signaling in T cells and contributes to cell survival. Oncogene 26, 7049-7057
28. Brock, C., Schaefer, M., Reusch, H.P., Czupalla, C., Michalke, M., Spicher, K., Schultz, G. and Nurnberg, B. (2003) Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ. J. Cell Biol. 160, 89-99
29. Krugmann, S., Cooper, M.A., Williams, D.H., Hawkins, P.T. and Stephens, L.R. (2002) Mechanism of the regulation of type IB phosphoinositide 3OH-kinase by G-protein βγ subunits. Biochem. J. 362, 725-731
30. 3 formation monitored by a fluorescent Gβγ biosensor protein and repetitive two component total internal reflection/fluorescence redistribution after photobleaching analysis. Biochemistry 47, 11239-11250
31. Falasca, M. and Maffucci, T. (2007) Role of class II phosphoinositide 3-kinase in cell signalling. Biochem. Soc. Trans. 35, 211-214
32. Gaidarov, I., Smith, M.E., Domin, J. and Keen, J.H. (2001) The class II phosphoinositide 3-kinase C2α is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell 7, 443-449
33. 2+-regulated pool of phosphatidylinositol 3-phosphate produced by phosphatidylinositol 3-kinase C2α on neurosecretory vesicles. Mol. Biol. Cell 19, 5593-5603
34. Meunier, F.A., Osborne, S.L., Hammond, G.R., Cooke, F.T., Parker, P.J., Domin, J. and Schiavo, G. (2005) Phosphatidylinositol 3-kinase C2α is essential for ATP-dependent priming of neurosecretory granule exocytosis. Mol. Biol. Cell 16, 4841-4851
35. Wang, Y., Yoshioka, K., Azam, M.A., Takuwa, N., Sakurada, S., Kayaba, Y., Sugimoto, N., Inoki, I., Kimura, T., Kuwaki, T. and Takuwa, Y. (2006) Class II phosphoinositide 3-kinase α-isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle. Biochem. J. 394, 581-592
36. Falasca, M., Hughes, W.E., Dominguez, V., Sala, G., Fostira, F., Fang, M.Q., Cazzolli, R., Shepherd, P.R., James, D.E. and Maffucci, T. (2007) The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. Chem. 282, 28226-28236
37. Brown, R.A., Domin, J., Arcaro, A., Waterfield, M.D. and Shepherd, P.R. (1999) Insulin activates the α isoform of class II phosphoinositide 3-kinase. J. Biol. Chem. 274, 14529-14532
38. Soos, M.A., Jensen, J., Brown, R.A., O'Rahilly, S., Shepherd, P.R. and Whitehead, J.P. (2001) Class II phosphoinositide 3-kinase is activated by insulin but not by contraction in skeletal muscle. Arch. Biochem. Biophys. 396, 244-248
39. Maffucci, T., Cooke, F.T., Foster, F.M., Traer, C.J., Fry, M.J. and Falasca, M. (2005) Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J. Cell Biol. 169, 789-799
40. Domin, J., Harper, L., Aubyn, D., Wheeler, M., Florey, O., Haskard, D., Yuan, M. and Zicha, D. (2005) The class II phosphoinositide 3-kinase PI3K-C2β regulates cell migration by a PtdIns3P dependent mechanism. J. Cell Physiol. 205, 452-462
41. Katso, R.M., Pardo, O.E., Palamidessi, A., Franz, C.M., Marinov, M., De Laurentiis, A., Downward, J., Scita, G., Ridley, A.J., Waterfield, M.D. and Arcaro, A. (2006) Phosphoinositide 3-kinase C2β regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol. Biol. Cell 17, 3729-3744
42. Das, M., Scappini, E., Martin, N.P., Wong, K.A., Dunn, S., Chen, Y.J., Miller, S.L., Domin, J. and O'Bryan, J.P. (2007) Regulation of neuron survival through an intersectin-phosphoinositide 3′-kinase C2β-Akt pathway. Mol. Cell. Biol. 27, 7906-7917
43. Wheeler, M. and Domin, J. (2006) The N-terminus of phosphoinositide 3-kinase-C2β regulates lipid kinase activity and binding to clathrin. J. Cell. Physiol. 206, 586-593
44. Stahelin, R.V., Karathanassis, D., Bruzik, K.S., Waterfield, M.D., Bravo, J., Williams, R.L. and Cho, W. (2006) Structural and membrane binding analysis of the Phox homology domain of phosphoinositide 3-kinase-C2α. J. Biol. Chem. 281, 39396-39406
45. Engelman, J.A., Luo, J. and Cantley, L.C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619
46. Schu, P.V., Takegawa, K., Fry, M.J., Stack, J.H., Waterfield, M.D. and Emr, S.D. (1993) Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 260, 88-91
47. Brown, W.J., DeWald, D.B., Emr, S.D., Plutner, H. and Balch, W.E. (1995) Role for phosphatidylinositol 3-kinase in the sorting and transport of newly synthesized lysosomal enzymes in mammalian cells. J. Cell Biol. 130, 781-796
48. Backer, J.M. (2008) The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J. 410, 1-17
49. Gulati, P. and Thomas, G. (2007) Nutrient sensing in the mTOR/S6K1 signalling pathway. Biochem. Soc. Trans. 35, 236-238
50. Nobukuni, T., Joaquin, M., Roccio, M., Dann, S.G., Kim, S.Y., Gulati, P., Byfield, M.P., Backer, J.M., Natt, F., Bos, J.L. et al. (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. U.S.A. 102, 14238-14243
51. Byfield, M.P., Murray, J.T. and Backer, J.M. (2005) hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280, 33076-33082
52. Kihara, A., Noda, T., Ishihara, N. and Ohsumi, Y. (2001) Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 152, 519-530
53. Itakura, E., Kishi, C., Inoue, K. and Mizushima, N. (2008) Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol. Biol. Cell 19, 5360-5372
54. Sun, Q., Fan, W., Chen, K., Ding, X., Chen, S. and Zhong, Q. (2008) Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 105, 19211-19216
55. Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B.H. and Jung, J.U. (2006) Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat. Cell Biol. 8, 688-699
56. Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H.D., Sun, M., Sato, Y., Liang, C., Jung, J.U., Cheng, J.Q., Mul, J.J. et al. (2007) Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat. Cell Biol. 9, 1142-1151
57. Liang, C., Lee, J.S., Inn, K.S., Gack, M.U., Li, Q., Roberts, E.A., Vergne, I., Deretic, V., Feng, P., Akazawa, C. and Jung, J.U. (2008) Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat. Cell Biol. 10, 776-787
58. Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R. and Wymann, M.P. (1998) Bifurcation of lipid and protein kinase signals of PI3Kγ to the protein kinases PKB and MAPK. Science 282, 293-296
59. Pirola, L., Zvelebil, M.J., Bulgarelli-Leva, G., Van Obberghen, E., Waterfield, M.D. and Wymann, M.P. (2001) Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα). J. Biol. Chem. 276, 21544-21554
60. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275-282
61. Liu, Y. and Gray, N.S. (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364
62. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942
63. Sadhu, C., Masinovsky, B., Dick, K., Sowell, C.G. and Staunton, D.E. (2003) Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J. Immunol. 170, 2647-2654
64. Condliffe, A.M., Davidson, K., Anderson, K.E., Ellson, C.D., Crabbe, T., Okkenhaug, K., Vanhaesebroeck, B., Turner, M., Webb, L., Wymann, M.P. et al. (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432-1440
65. Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B. et al. (2005) Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-943
66. Barber, D.F., Bartolome, A., Hernandez, C., Flores, J.M., Redondo, C., Fernandez-Arias, C., Camps, M., Ruckle, T., Schwarz, M.K., Rodriguez, S. et al. (2005) PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935
67. Knight, Z.A., Chiang, G.G., Alaimo, P.J., Kenski, D.M., Ho, C.B., Coan, K., Abraham, R.T. and Shokat, K.M. (2004) Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12, 4749-4759
68. Walker, E.H., Pacold, M.E., Perisic, O., Stephens, L., Hawkins, P.T., Wymann, M.P. and Williams, R.L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909-919
69. Folkes, A.J., Ahmadi, K., Alderton, W.K., Alix, S., Baker, S.J., Box, G., Chuckowree, I.S., Clarke, P.A., Depledge, P., Eccles, S.A. et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin- 1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522-5532
70. Xie, P., Williams, D.S., Atilla-Gokcumen, G.E., Milk, L., Xiao, M., Smalley, K.S., Herlyn, M., Meggers, E. and Marmorstein, R. (2008) Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 3, 305-316
71. Perry, B., Alexander, R., Bennett, G., Buckley, G., Ceska, T., Crabbe, T., Dale, V., Gowers, L., Horsley, H., James, L. et al. (2008) Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2 H-benzo[1,4]oxazines. Bioorg. Med. Chem. Lett. 18, 4700-4704
72. Huang, C.H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Gabelli, S.B. and Amzel, L.M. (2007) The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 318, 1744-1748
73. Pomel, V., Klicic, J., Covini, D., Church, D.D., Shaw, J.P., Roulin, K., Burgat-Charvillon, F., Valognes, D., Camps, M., Chabert, C. et al. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem. 49, 3857-3871
74. Kuang, R.R., Qian, F., Li, Z. and Wei, D.Z. (2006) Study on improving the selectivity of compounds that inhibit two PI3Ks (γ and δ). J. Mol. Model. 12, 445-452
75. Kuang, R.R., Qian, F., Li, Z., Wei, D.Z. and Tang, Y. (2006) Action mechanisms and structure-activity relationships of PI3Kγ inhibitors on the enzyme: a molecular modeling study. Eur. J. Med. Chem. 41, 558-565
76. Frazzetto, M., Suphioglu, C., Zhu, J., Schmidt-Kittler, O., Jennings, I.G., Cranmer, S.L., Jackson, S.P., Kinzler, K.W., Vogelstein, B. and Thompson, P.E. (2008) Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem. J. 414, 383-390
77. Zhao, L. and Vogt, P.K. (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496
78. Samuels, Y., Diaz, L.A.J., Schmidt-Kittler, O., Cummins, J.M., Delong, L., Cheong, I., Rago, C., Huso, D.L., Lengauer, C., Kinzler, K.W. et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573
79. Samuels, Y. and Ericson, K. (2006) Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77-82
80. Vogt, P.K., Kang, S., Elsliger, M.A. and Gymnopoulos, M. (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 32, 342-349
81. Bader, A.G., Kang, S. and Vogt, P.K. (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 1475-1479
82. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068
83. Philp, A.J., Campbell, I.G., Leet, C., Vincan, E., Rockman, S.P., Whitehead, R.H., Thomas, R.J. and Phillips, W.A. (2001) The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426-7429
84. Kang, S., Bader, A.G. and Vogt, P.K. (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807
85. Carson, J.D., Van Aller, G., Lehr, R., Sinnamon, R.H., Kirkpatrick, R.B., Auger, K.R., Dhanak, D., Copeland, R.A., Gontarek, R.R., Tummino, P.J. and Luo, L. (2008) Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem. J. 409, 519-524
86. Gymnopoulos, M., Elsliger, M.A. and Vogt, P.K. (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. U.S.A. 104, 5569-5574
87. Bachman, K.E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B.G., Lin, C. et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772-775
88. Mankoo, P.K., Sukumar, S. and Karchin, R. (2009) PIK3CA somatic mutations in breast cancer: mechanistic insights from Langevin dynamics simulations. Proteins 75, 499-508
89. Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z.A., Shokat, K.M. and McCormick, F. (2008) PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 68, 8127-8136
90. Zhao, L. and Vogt, P.K. (2008) Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 2652-2657
91. Chaussade, C., Cho, K., Mawson, C., Rewcastle, G.W. and Shepherd, P.R. (2009) Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem. Biophys. Res. Commun. 381, 577-581
92. Sujobert, P., Bardet, V., Cornillet-Lefebvre, P., Hayflick, J.S., Prie, N., Verdier, F., Vanhaesebroeck, B., Muller, O., Pesce, F., Ifrah, N. et al. (2005) Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066
93. Billottet, C., Grandage, V.L., Gale, R.E., Quattropani, A., Rommel, C., Vanhaesebroeck, B. and Khwaja, A. (2006) A selective inhibitor of the p110d isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648-6659
94. Kang, S., Denley, A., Vanhaesebroeck, B. and Vogt, P.K. (2006) Oncogenic transformation induced by the p110β, γ, and -δ isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 103, 1289-1294
95. Vogt, P.K., Gymnopoulos, M. and Hart, J.R. (2009) PI 3-kinase and cancer: changing accents. Curr. Opin. Genet. Dev. 19, 12-17
96. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S.H., Zhang, J., Signoretti, S., Loda, M., Roberts, T.M. and Zhao, J.J. (2008) Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454, 776-779
97. Maira, S.-M., Stauffer, F., Schnell, C. and García-Echeverría, C. (2009) PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans. 37, 265-272
98. Kong, D. and Yamori, T. (2008) Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 99, 1734-1740
99. Ihle, N.T. and Powis, G. (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther. 8, 1-9
100. Yap, T.A., Garrett, M.D., Walton, M.I., Raynaud, F., de Bono, J.S. and Workman, P. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412
101. Zvelebil, M.J., Waterfield, M.D. and Shuttleworth, S.J. (2008) Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch. Biochem. Biophys. 477, 404-410
102. Apsel, B., Blair, J.A., Gonzalez, B., Nazif, T.M., Feldman, M.E., Aizenstein, B., Hoffman, R., Williams, R.L., Shokat, K.M. and Knight, Z.A. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699
103. Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S.D. et al. (2004) PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375-387
104. Bi, L., Okabe, I., Bernard, D.J. and Nussbaum, R.L. (2002) Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome 13, 169-172
105. Christoforidis, S., Miaczynska, M., Ashman, K., Wilm, M., Zhao, L., Yip, S.C., Waterfield, M.D., Backer, J.M. and Zerial, M. (1999) Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell Biol. 1, 249-252
106. Shin, H.W., Hayashi, M., Christoforidis, S., Lacas-Gervais, S., Hoepfner, S., Wenk, M.R., Modregger, J., Uttenweiler-Joseph, S., Wilm, M., Nystuen, A. et al. (2005) An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J. Cell Biol. 170, 607-618
107. Oudit, G.Y., Crackower, M.A., Eriksson, U., Sarao, R., Kozieradzki, I., Sasaki, T., Irie-Sasaki, J., Gidrewicz, D., Rybin, V.O., Wada, T. et al. (2003) Phosphoinositide 3-kinase γ-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147-2152
108. 2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/β-arrestin complex. J. Cell Biol. 158, 563-575
109. Perrino, C., Schroder, J.N., Lima, B., Villamizar, N., Nienaber, J.J., Milano, C.A. and Naga Prasad, S.V. (2007) Dynamic regulation of phosphoinositide 3-kinase-γ activity and β-adrenergic receptor trafficking in end-stage human heart failure. Circulation 116, 2571-2579
110. Nienaber, J.J., Tachibana, H., Naga Prasad, S.V., Esposito, G., Wu, D., Mao, L. and Rockman, H.A. (2003) Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112, 1067-1079